Key Clinical Summary

• Federal policy volatility—including litigation, executive orders, and tariff actions—is creating uncertainty in vaccine coverage, drug pricing, and payer decision-making.
• HR1 implementation introduces Medicaid eligibility changes, community engagement requirements, and limits on retroactive coverage beginning in 2026-2027.
• Emerging models (eg, most-favored-nation (MFN) pricing, GLP-1 demonstrations) and pharmacy benefit manager (PBM) reforms signal continued federal focus on cost containment and transparency.

A panel of experts at the 2026 Academy of Managed Care Pharmacy (AMCP) conference discussed significant federal legislative and regulatory developments shaping US health policy. The session emphasized increasing uncertainty in vaccine policy, drug pricing reforms, and payer obligations, with implications for managed care organizations navigating evolving federal requirements and market pressures.

Federal Policy and Regulatory Developments

Adam Colborn, JD, vice president of government affairs at AMCP, and Geni Tunstall, JD, associate vice president of regulatory affairs at AMCP, outlined a turbulent federal policy environment marked by litigation, executive actions, and shifting regulatory priorities.

A key focus was vaccine policy disruption. Changes to the Advisory Committee on Immunization Practices (ACIP), including restructuring and court challenges, have delayed recommendations and created uncertainty in coverage mandates tied to the Affordable Care Act (ACA). Because ACIP recommendations trigger mandatory coverage without cost sharing, instability may directly affect payer benefit design.

The speakers reviewed HR1 implementation timelines, including Medicaid policy changes such as community engagement requirements, eligibility redeterminations, and limits on retroactive coverage beginning January 2027. These provisions may increase administrative burden for states and plans while affecting beneficiary access.

Drug pricing reforms were another central theme. The administration’s use of tariffs—up to 20% on pharmaceuticals and 100% without MFN agreements—links global trade policy to domestic drug costs. Concurrently, MFN pricing strategies and Center for Medicare and Medicaid Innovation (CMMI) models (eg, Generous, GLOBE, and Guard) aim to align US prices with international benchmarks across Medicaid, Medicare Part B, and Part D.

The session also highlighted Medicare Advantage updates, including a finalized 2.48% payment increase and continued risk adjustment model changes. Additionally, GLP-1–focused initiatives, such as the Medicare GLP-1 Bridge program and Centers for Medicare & Medicaid Services (CMS) demonstration models, reflect growing federal attention to high-cost therapies for obesity and metabolic disease.

Finally, Consolidated Appropriations Act (CAA) provisions introduced significant PBM reforms, including rebate pass-through requirements, delinked compensation models, and expanded transparency reporting across Medicare and Employee Retirement Income Security Act of 1974 (ERISA) plans.

Stakeholder Insights and Policy Interpretation

According to Colborn, the current policy environment combines “business as usual” with atypical turbulence, including rapid executive actions and inconsistent messaging strategies. He noted that such instability complicates long-term planning for payers and manufacturers.

Tunstall emphasized that tariff policies and MFN pricing initiatives are likely to sustain volatility in drug pricing. She highlighted that payer strategies must account for evolving acquisition costs and manufacturer pricing behaviors tied to international benchmarks.

Both speakers underscored concerns about PBM reforms. While transparency requirements may improve visibility, experts questioned their practical impact, noting uncertainty about whether additional data would meaningfully change payer or employer decision-making.

The panel also discussed increasing scrutiny of vertical integration across insurers, PBMs, and providers, as well as potential legislative actions affecting the 340B program and drug supply chain stakeholders. These developments signal a broader policy shift beyond PBMs to the entire pharmaceutical distribution ecosystem.

Impact on Payers, Coverage, and Market Access

For managed care professionals, these developments underscore the need for adaptive strategies in benefit design, contracting, and compliance. Vaccine policy uncertainty may affect coverage decisions, while HR1 implementation will require operational adjustments. Drug pricing reforms, including MFN models and tariffs, could influence formulary management and cost projections. Increased transparency and PBM regulation may also reshape contracting practices and reporting requirements.

Outlook for Federal Health Policy and Drug Pricing

This session highlighted a rapidly evolving federal policy landscape with significant implications for payers and health care stakeholders. Ongoing litigation, regulatory changes, and emerging pricing models will require close monitoring as agencies and Congress refine policies affecting drug costs, coverage, and care delivery.

Reference

Colborn A, Tunstall G. Federal Legislative and Regulatory Update. Presented at: AMCP 2026; April 13-15; Nashville, TN.